Kiniksa Pharmaceuticals International PLC
KNSA32.854USD
+0.874+2.73%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
2.43BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Kiniksa Pharmaceuticals International PLC Unternehmen
Kiniksa Pharmaceuticals International, plc is a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Its portfolio of immune-modulating assets, ARCALYST, abiprubart and mavrilimumab, is based on strong biologic rationale or validated mechanisms, targets a spectrum of underserved cardiovascular and autoimmune conditions and offers the potential for differentiation. ARCALYST is an interleukin-1α and interleukin-1β cytokine trap. ARCALYST is used for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and children 12 years and older. ARCALYST is also approved for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome, and the maintenance of remission in Deficiency of Interleukin-1 Receptor Antagonist.
Unternehmensinformationen
BörsenkürzelKNSA
Name des UnternehmensKiniksa Pharmaceuticals International PLC
IPO-datumMay 24, 2018
CEOMr. Sanjiv K. (Sanj) Patel
Anzahl der mitarbeiter315
WertpapierartOrdinary Share
GeschäftsjahresendeMay 24
Addresse23 Old Bond Street, Floor 3
StadtLONDON
BörseNASDAQ Global Select Consolidated
LandUnited Kingdom
PostleitzahlWIS 4PZ
Telefon
Websitehttps://www.kiniksa.com/
BörsenkürzelKNSA
IPO-datumMay 24, 2018
CEOMr. Sanjiv K. (Sanj) Patel
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Sanjiv K. (Sanj) Patel
Mr. Sanjiv K. (Sanj) Patel
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
206.47K
--
Mr. Thomas Robert (Tom) Malley
Mr. Thomas Robert (Tom) Malley
Independent Director
Independent Director
84.51K
+3.90%
Dr. John F. Paolini, M.D., Ph.D.
Dr. John F. Paolini, M.D., Ph.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
57.40K
--
Mr. Eben Tessari
Mr. Eben Tessari
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
49.16K
-20.14%
Mr. Mark Ragosa
Mr. Mark Ragosa
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
27.01K
--
Dr. Felix J. Baker, Ph.D.
Dr. Felix J. Baker, Ph.D.
Lead Independent Director
Lead Independent Director
24.21K
+63.16%
Dr. Richard S. Levy, M.D.
Dr. Richard S. Levy, M.D.
Independent Director
Independent Director
18.47K
+6.34%
Dr. Barry D. Quart, Pharm.D.
Dr. Barry D. Quart, Pharm.D.
Independent Director
Independent Director
12.55K
+33.85%
Ms. Kimberly J. (Kim) Popovits
Ms. Kimberly J. (Kim) Popovits
Independent Director
Independent Director
12.55K
--
Mr. Ross Moat
Mr. Ross Moat
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
9.41K
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Sanjiv K. (Sanj) Patel
Mr. Sanjiv K. (Sanj) Patel
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
206.47K
--
Mr. Thomas Robert (Tom) Malley
Mr. Thomas Robert (Tom) Malley
Independent Director
Independent Director
84.51K
+3.90%
Dr. John F. Paolini, M.D., Ph.D.
Dr. John F. Paolini, M.D., Ph.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
57.40K
--
Mr. Eben Tessari
Mr. Eben Tessari
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
49.16K
-20.14%
Mr. Mark Ragosa
Mr. Mark Ragosa
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
27.01K
--
Dr. Felix J. Baker, Ph.D.
Dr. Felix J. Baker, Ph.D.
Lead Independent Director
Lead Independent Director
24.21K
+63.16%
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Thu, May 22
Aktualisiert: Thu, May 22
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Rubric Capital Management LP
8.99%
The Vanguard Group, Inc.
7.71%
Baker Bros. Advisors LP
6.48%
BlackRock Institutional Trust Company, N.A.
5.78%
Tang Capital Management, LLC
4.87%
Other
66.16%
Aktionäre
Aktionäre
Anteil
Rubric Capital Management LP
8.99%
The Vanguard Group, Inc.
7.71%
Baker Bros. Advisors LP
6.48%
BlackRock Institutional Trust Company, N.A.
5.78%
Tang Capital Management, LLC
4.87%
Other
66.16%
Aktionärstypen
Aktionäre
Anteil
Hedge Fund
41.14%
Investment Advisor
27.15%
Investment Advisor/Hedge Fund
25.63%
Individual Investor
3.86%
Research Firm
2.27%
Pension Fund
0.59%
Bank and Trust
0.30%
Insurance Company
0.11%
Family Office
0.10%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
393
42.78M
98.41%
-554.60K
2025Q1
407
42.98M
101.69%
-650.43K
2024Q4
391
41.95M
99.92%
-5.07M
2024Q3
382
42.52M
104.55%
-472.80K
2024Q2
354
38.32M
94.71%
-9.35M
2024Q1
340
41.61M
104.40%
+110.03K
2023Q4
319
36.70M
103.36%
-5.01M
2023Q3
318
37.56M
105.96%
-4.22M
2023Q2
312
35.54M
100.99%
-4.88M
2023Q1
303
35.17M
100.37%
-5.41M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Rubric Capital Management LP
3.38M
7.99%
+764.14K
+29.18%
Mar 31, 2025
The Vanguard Group, Inc.
3.35M
7.91%
+151.60K
+4.74%
Mar 31, 2025
Baker Bros. Advisors LP
2.82M
6.66%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
2.51M
5.94%
-39.60K
-1.55%
Mar 31, 2025
Tang Capital Management, LLC
2.12M
5%
+1.49M
+237.03%
Mar 31, 2025
Braidwell LP
1.96M
4.64%
-1.49M
-43.14%
Mar 31, 2025
Point72 Asset Management, L.P.
1.15M
2.71%
+1.15M
--
Mar 31, 2025
Pictet Asset Management Ltd.
1.13M
2.68%
--
--
Mar 31, 2025
Fairmount Funds Management LLC
1.10M
2.6%
+1.10M
--
Mar 31, 2025
Desnick (Robert)
1.05M
2.48%
--
--
Apr 08, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
Virtus LifeSci Biotech Products ETF
1.92%
First Trust Active Factor Small Cap ETF
0.54%
VictoryShares Small Cap Free Cash Flow ETF
0.53%
iShares Health Innovation Active ETF
0.24%
iShares MSCI USA Small-Cap Min Vol Factor ETF
0.15%
WisdomTree US SmallCap Fund
0.15%
ProShares Ultra Nasdaq Biotechnology
0.13%
Invesco Nasdaq Biotechnology ETF
0.13%
Fidelity Enhanced Small Cap ETF
0.11%
iShares Micro-Cap ETF
0.04%
Mehr Anzeigen
Virtus LifeSci Biotech Products ETF
Anteil1.92%
First Trust Active Factor Small Cap ETF
Anteil0.54%
VictoryShares Small Cap Free Cash Flow ETF
Anteil0.53%
iShares Health Innovation Active ETF
Anteil0.24%
iShares MSCI USA Small-Cap Min Vol Factor ETF
Anteil0.15%
WisdomTree US SmallCap Fund
Anteil0.15%
ProShares Ultra Nasdaq Biotechnology
Anteil0.13%
Invesco Nasdaq Biotechnology ETF
Anteil0.13%
Fidelity Enhanced Small Cap ETF
Anteil0.11%
iShares Micro-Cap ETF
Anteil0.04%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
